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30Background: To date, reported surgical morbidity and mortality for pleurectomy/decortication and extrapleural
pneumonectomy performed for malignant pleural mesothelioma primarily represent the experience of a few
specialized centers. For comparison, we examined early outcomes of pleurectomy/decortication and
extrapleural pneumonectomy from a broader group of centers/surgeons participating in the Society of Thoracic
Surgeons-General Thoracic Database.
Methods: All patients in the Society of Thoracic Surgeons-General Thoracic Database (version 2.081,
representing 2009-2011) who underwent pleurectomy/decortication or extrapleural pneumonectomy for
malignant pleural mesothelioma were identified. Patient characteristics, morbidity, mortality, center volume,
and procedure were examined using univariable and multivariable analyses.
Results:A total of 225 patients underwent pleurectomy/decortication (n¼ 130) or extrapleural pneumonectomy
(n ¼ 95) for malignant pleural mesothelioma at 48 centers. Higher volumes of procedures (5/y) were
performed at 3 pleurectomy/decortication and 2 extrapleural pneumonectomy centers. Patient characteristics
were statistically equivalent between pleurectomy/decortication and extrapleural pneumonectomy groups,
except those undergoing extrapleural pneumonectomy were younger (63.2  7.8 years vs 68.3  9.5 years;
P < .001) and more likely to have received preoperative chemotherapy (30.1% vs 17.8%; P ¼ .036).
Major morbidity was greater after extrapleural pneumonectomy, including acute respiratory distress syndrome
(8.4% vs 0.8%; P ¼ .005), reintubation (14.7% vs 2.3%; P ¼ .001), unexpected reoperation (9.5% vs 1.5%;
P¼ .01), and sepsis (4.2% vs 0%; P¼ .03), as was mortality (10.5% vs 3.1%; P¼ .03). Multivariate analyses
revealed that extrapleural pneumonectomy was an independent predictor of major morbidity or mortality
(odds ratio, 6.51; P¼ .001). Compared with high-volume centers, increased acute respiratory distress syndrome
was seen in low-volume centers performing extrapleural pneumonectomy (0% vs 12.5%; P ¼ .05).
Conclusions: Extrapleural pneumonectomy is associated with greater morbidity and mortality compared
with pleurectomy/decortication when performed by participating surgeons of the Society of Thoracic
Surgeons-General Thoracic Database. Effects of center volume require further study. (J Thorac Cardiovasc Surg
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The Journal of Thoracic and Cardiovascular SurgeMalignant pleural mesothelioma (MPM) is an aggressive
malignancy of the pleura associated with a median survival
of only 4 to 19 months.1-3 Epidemiologic studies suggest
that the incidence of MPM worldwide is underestimated
and increasing.4,5 The available, albeit limited, data on
the treatment of patients with MPM suggest that
multimodality therapy produces superior results compared
with other strategies; however, the exact role of surgery in
the treatment program has been controversial, and most of
these data are derived from retrospective studies with
known selection and reporting biases.6,7 Macroscopic
complete resection is thought to be the most achievable
goal of surgical resection, but the optimal cytoreductive
procedure is debated.
Extrapleural pneumonectomy (EPP) entails en bloc
resection of the parietal pleura, lung, ipsilateral hemidiaph-
ragm, and pericardium, with pericardial and diaphragmatic
reconstruction. Pleurectomy/decortication (PD) involves
resection of the parietal and visceral pleura, but spares the
lung. Pericardial or diaphragmatic resection may bery c July 2014
Abbreviations and Acronyms
ARDS ¼ acute respiratory distress syndrome
EPP ¼ extrapleural pneumonectomy
MPM ¼ malignant pleural mesothelioma
PD ¼ pleurectomy/decortication
STS-GTD ¼ Society of Thoracic Surgeons-General
Thoracic Database
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procedure argue the oncologic merits of each operation,
but to date, a long-term survival advantage of one over
the other has not been clearly shown. The role of surgery
in the treatment of MPM became further debated after
publication of the Mesothelioma and Radical Surgery
(MARS) trial in 2011, which attempted to compare EPP
with no EPP in patients with MPM.8 The authors concluded
that EPP within the context of trimodality therapy did not
offer benefit; however, this trial was criticized for factors,
including study design, small sample size, and high rate
of mortality after EPP.9,10
The relative morbidity and mortality of PD and EPP are
consistently reported in the literature. Although EPP seems
to have a substantially greater morbidity and mortality than
PD, the available data are largely from single institution
studies and are representative of specialized centers. In a
retrospective review of 663 patients with MPM treated
with EPP or PD at 3 institutions, operative mortality rates
of 7% for EPP and 4% for PD were reported, and rates
of severe (grade 3-5) postoperative adverse events were
18.7% in EPP and 8.3% in PD.6 A systematic review of
34 series comprising 2463 patients undergoing EPP at 26
institutions demonstrated perioperative mortality rates of
EPP that ranged from 0% to 11.8%, with a median value
of 5.5%. Overall perioperative complication rates for EPP
were 22% to 82%, with 12.5% to 48% major morbidity.11
In a separate systematic review of 1270 patients undergoing
PD for MPM within 26 series, operative mortality ranged
from 0% to 25%, with a weighted average of 4%.12 Similar
to other complex procedures, such as pneumonectomy
and esophagectomy, the morbidity and mortality of EPP
(and PD) might be expected to be lower at higher-volume
centers,13-15 although this remains unproven.
To more clearly define the morbidity and mortality of
both PD and EPP, reflected by the experience of a broad
range of thoracic surgeons and institutions, we reviewed
data from the Society of Thoracic Surgeons-General
Thoracic Database (STS-GTD). This database currently
includes data from approximately 827 surgeons from 238
institutions across the United States. Within this construct,
we examined the incidence of major complications and
death for each procedure and identified predictive factors.The Journal of Thoracic and COur hypothesis was that, among participants of the
STS-GTD, EPP results in greater morbidity and mortality
than does PD for patients with MPM. We also attempted
to evaluate the contribution of center volume on postopera-
tive morbidity and mortality after each of these procedures.METHODS
Database and Patients
The research performed at Duke Clinical Research Institute on the
STS-GTD is approved by the Duke University Institutional Review Board
and was granted a waiver of informed consent and Health Insurance
Portability and Accountability Act authorization. Individual participating
institution’s data collection is approved by the local institutional review
board to ensure that patient privacy and confidentiality are protected.
The STS-GTD, version 2.081 (2009-2011) was queried to identify patients
with the diagnosis of ‘‘pleural tumor, malignant (eg, mesothelioma)
163.9,’’ who underwent EPP (Current Procedural Terminology ¼ 32445;
n ¼ 95) or PD (Current Procedural Terminology¼ 32320; n ¼ 130). Prior
versions of the STS-GTD did not distinguish between primary and
secondary pleural tumors and were therefore not queried. Patients
undergoing incomplete procedures, that is, ‘‘decortication, pulmonary-
total, (32220),’’ ‘‘decortication, pulmonary-partial, (32225),’’ and
‘‘pleurectomy, parietal (32310),’’ were excluded. The number of PD and
EPP procedures performed annually in each of the participating centers
was recorded.
Definitions
Mortality was defined as death within 30 days, or before discharge.
Major postoperative complications after PD or EPP were considered to
be acute respiratory distress syndrome (ARDS), bronchopleural fistula,
pneumonia, reintubation, placement of tracheostomy, pulmonary embolus,
empyema, sepsis, myocardial infarction, ventricular arrhythmia requiring
treatment, bleeding requiring reoperation, and unexpected return to the
operating room. Minor complications included atrial arrythmias and
prolonged air leak.
Statistical Analysis
The study design was approved by the Society of Thoracic Surgeons
Access & Publications Committee, and statistical analyses were performed
at the Duke Clinical Research Institute according to Society of Thoracic
Surgeons protocol. Comparisons were performed using the 2-sample
nonparametric Wilcoxon test for continuous variables and the Fisher exact
test for categoric variables. To identify correlates of major morbidity and
mortality, logistic regression analyses were performed. When developing
the multivariable model, we first considered univariable logistic
regressions to evaluate univariable associations of each variable in
Table 1 with the presence of major morbidity or mortality. The
multivariable analysis initially considered variables with a univariable
probability value of less than .10. The model fits well as indicated by a
not significant Hosmer–Lemeshow goodness-of-fit test (P ¼ .34).
The Nagelkerke R-square is 0.30 and C-statistic is 0.80.RESULTS
Centers and Patients
During the study period, 286 patients with a diagnosis of
MPM underwent pleural procedures. Eighteen patients
undergoing ‘‘decortication, pulmonary-total,’’ 13 patients un-
dergoing ‘‘decortication, pulmonary-partial,’’ and 30 patients
undergoing ‘‘pleurectomy, parietal’’ were excluded asardiovascular Surgery c Volume 148, Number 1 31
TABLE 1. Patient characteristics
Characteristic
PD
n ¼ 130
EPP
n ¼ 95 P value
Age (mean  SD) 68.3  9.5 63.2  7.8 <.001
Male 104 (80) 80 (84.2) .49
Race .64
Caucasian 116 (90.6) 86 (90.5)
Black 5 (3.9) 6 (6.3)
Hispanic 5 (3.9) 3 (3.2)
Body mass index 27.3  3.6 27.2  4.1 .77
Smoking history .40
Never 51 (39.2) 45 (47.4)
Past or current 79 (60.8) 50 (52.7)
FEV1% (mean  SD) 72.9  21.3 73.3  16.3 .84
DLCO% (mean  SD) 74.0  26.3 74.5  18.4 .98
ASA risk class .22
I 0 (0.0) 1 (1.1)
II 23 (17.7) 10 (10.5)
III 98 (75.4) 74 (77.9)
IV 9 (6.9) 9 (9.5)
V 0 (0.0) 1 (1.1)
Zubrod score .50
0 30 (23.1) 16 (16.8)
1 86 (66.2) 70 (73.7)
2 10 (7.7) 8 (5.4)
3 4 (3.1) 1 (1.1)
Coronary artery disease 13 (10.1) 9 (9.7) 1.0
Congestive heart failure 1 (0.8) 0 (0.0) 1.0
Hypertension 66 (51.2) 54 (56.8) .42
Peripheral vascular disease 2 (1.3) 5 (5.4) .13
Cerebral vascular disease 1 (0.8) 3 (3.3) .31
COPD 6 (4.7) 10 (10.8) .11
Diabetes 17 (13.2) 10 (10.8) .68
Pulmonary hypertension 0 (0.0) 2 (2.2) .11
Last creatinine level (mean  SD) 1.0  0.3 1.0  0.3 .99
Last hemoglobin level (mean  SD) 12.5  1.9 12.3  1.9 .63
Preoperative chemotherapy 23 (17.8) 28 (30.1) .036
Preoperative radiotherapy 1 (0.8) 2 (2.2) .57
Steroid use 0 (0.0) 1 (1.1) .42
ASA, American Association of Anesthesiology; COPD, chronic obstructive
pulmonary disease; DLCO, diffusing capacity of the lungs for carbon monoxide;
EPP, extrapleural pneumonectomy; FEV1, forced expiratory volume in 1 second;
PD, pleurectomy/decortication; SD, standard deviation.
FIGURE 1. Number of PDs (A) and EPPs (B) performed in
patients with MPM at each of the 48 participating centers during the
3-year time period of this study. EPP, Extrapleural pneumonectomy;
PD, pleurectomy/decortication.
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Sinadequate oncologic operations. The final study cohort con-
sisted of 130 patients undergoing PD and 95 patients undergo-
ing EPP.
At least 1 operation for MPM, either PD or EPP, was
performed among 48 participating centers during the study
period of 3 years. Twenty-four centers performed PD, 37
centers performed EPP, and 13 centers performed both PD
and EPP. Higher-volume centers performed 15 PD or EPP
operations during the study period (5/y) (Figure 1). By us-
ing this criterion, only 3 centers qualified as higher-volume
PD centers, and only 2 centers qualified as higher-volume
EPP centers. Only one of these centers qualified as a
higher-volume center for both PD and EPP.32 The Journal of Thoracic and Cardiovascular SurgePatient Characteristics
Comparisons of preoperative characteristics between
patients in the PD and EPP groups are shown in Table 1.
The PD and EPP groups were statistically similar with 2 ex-
ceptions: Patients in the EPP group were younger than
patients undergoing PD, and they more frequently received
preoperative chemotherapy than patients in the PD group.
There were no statistical differences in performance status,
American Association of Anesthesiology risk classification,
pulmonary function, or medical comorbidities between PD
and EPP groups. Of the 225 patients, 36 (16%) underwent
cervical mediastinoscopy before their EPP or PD operation.
Twenty-three patients (24.2%) undergoing EPP and
13 patients (10%) undergoing PD underwent cervical
mediastinoscopy. Staging data were not captured in this
version of the STS-GTD.Morbidity and Mortality
Table 2 displays the rates of major postoperative
morbidities and mortality after PD and EPP. Compared
with patients undergoing PD, patients undergoing EPP
had significantly higher rates of ARDS (8.4% vs 0.8%),
reintubation (14.7% vs 2.3%), sepsis (4.2% vs 0%), and
unexpected return to the operating room (9.5% vs 1.5%).ry c July 2014
TABLE 2. Rates of major postoperative morbidity and mortality in
patients undergoing pleurectomy/decortication or extrapleural
pneumonectomy for malignant pleural mesothelioma
Event
PD
n ¼ 130
EPP
n ¼ 95 P value
ARDS 1 (0.8) 8 (8.4) .005
Bronchopleural fistula 0 (0.0) 1 (1.1) .42
Pneumonia 3 (2.3) 5 (5.3) .29
Reintubation 3 (2.3) 14 (14.7) .001
Tracheostomy 3 (2.3) 7 (7.4) .10
Pulmonary embolus 2 (1.5) 0 (0.0) .51
Empyema 1 (0.8) 1 (1.1) 1.0
Sepsis 0 (0.0) 4 (4.2) .031
Myocardial infarction 1 (0.8) 2 (2.1) .57
Ventricular arrhythmia requiring treatment 1 (0.8) 2 (2.1) .57
Bleeding requiring reoperation 0 (0.0) 0 (0.0) 1.0
Unexpected return to the operating room 2 (1.5) 9 (9.5) .010
At least 1 major complication 5 (3.8) 23 (24.2) <.001
Mortality 4 (3.1) 10 (10.5) .027
At least 1 major complication or mortality 6 (4.6) 24 (25.3) <.001
ARDS, Acute respiratory distress syndrome; EPP, extrapleural pneumonectomy;
PD, pleurectomy/decortication.
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tracheostomy placed. EPP was associated with a
significantly higher rate of postoperative mortality
(10.5%) than was PD (3.1%). Other complications are
shown in Table 3 and include atrial arrhythmias requiring
treatment (41.1% vs 11.5%) in those undergoing EPP or
PD. Prolonged air leak was observed in 23.1% of patients
undergoing PD and in 1.1% of patients undergoing EPP,
where this represented a bronchopleural fistula.Determinants of Postoperative Morbidity and
Mortality
Univariable and multivariable models were constructed
to determine whether procedure (EPP or PD) wasTABLE 3. Other postoperative events in patients undergoing
pleurectomy/decortication or extrapleural pneumonectomy for
malignant pleural mesothelioma
Event
PD
n ¼ 130
EPP
n ¼ 95 P value
Air leak>5 d duration 30 (23.1) 1 (1.1) N/A
Atelectasis requiring bronchoscopy 1 (0.8) 3 (3.2) .31
Initial ventilator support>48 h 2 (1.5) 4 (4.2) .24
Atrial arrhythmia requiring treatment 15 (11.5) 39 (41.1) <.001
DVT requiring treatment 1 (0.8) 2 (2.1) .57
Wound infection 1 (0.8) 2 (2.1) .57
Recurrent laryngeal nerve paresis 0 (0.0) 2 (2.1) .18
Renal failure 4 (3.1) 8 (8.4) .13
Chylothorax 1 (0.8) 0 (0.0) 1.0
Unexpected admission to ICU 5 (3.8) 9 (9.5) .099
Length of stay (mean d  SD) 8.1  8.7 10  7.4 .001
DVT, Deep vein thrombosis; EPP, extrapleural pneumonectomy; ICU, intensive care
unit; PD, pleurectomy/decortication; SD, standard deviation; N/A, not compared.
The Journal of Thoracic and Cindependently associated with major postoperative
morbidity or mortality in patients undergoing cytoreductive
surgery for MPM. Table 4 displays the significant univari-
able predictors, as well as the corresponding multivariable
model for these variables. Univariable predictors of major
postoperative morbidity and mortality included operation
type (EPP), center volume (<5 procedures per year),
peripheral vascular disease, cerebrovascular disease, and
lower preoperative hemoglobin level. In the multivariable
model, procedure type (EPP) and cerebrovascular disease
were retained as independent predictors of major
postoperative morbidity or mortality.
Center Volume
A comparison of all preoperative characteristics listed in
Table 1 was performed for patients undergoing PD at
higher- and lower-volume PD centers, and separately for
patients undergoing EPP at higher- or lower-volume EPP
centers. There were no statistically significant differences
in preoperative variables among these groups except that
patients who underwent PD at higher-volume centers
were more likely to have a lower American Association
of Anesthesiology risk class (I-II: 21.6%, III: 77.5%,
IV-V: 1.0%) than those who underwent PD at lower-
volume centers (I-II: 3.6%, III: 67.9%, IV-V: 28.6%;
P<.001). No differences in major postoperative morbidity
or mortality were found between higher- or lower-volume
PD centers. When examining EPP centers, there was a trend
toward a higher rate of ARDS in lower-volume centers
when compared with higher-volume centers (12.5% vs
0.0%; P ¼ .05) (Table 5). The mortality rate after
EPP was 6.5% at higher-volume centers and 12.5% at
lower-volume centers, although this difference was not
statistically significant (P ¼ .49).
DISCUSSION
The treatment of patients with MPM often involves a
coordinated multimodality treatment approach that
incorporates surgery, systemic therapy (chemotherapy),
and radiation. Although the role of surgery in the
treatment of MPM remains controversial, many think that
macroscopic complete resection improves long-term
outcome in these patients.3 However, a surgical standard
of care for patients with MPM has not been established.
Comparisons of survival and recurrence outcomes
between PD and EPP have been flawed by their mostly
retrospective nature, imbalanced patient characteristics,
and varying adjuvant treatments. Whereas EPP may be
associated with improved rates of local control (33% local
recurrence) compared with PD (65% local recurrence),6
several historical series have suggested that patients with
MPM treated with PD may have an overall better median
survival than after EPP.16 Conversely, a recent retrospective
analysis of the International Association for the Study ofardiovascular Surgery c Volume 148, Number 1 33
TABLE 4. Univariable and multivariable analyses for predictors of major postoperative morbidity or mortality
Event
Univariate Multivariate
OR (95% CI) P value OR (95% CI) P value
Procedure (EPP) 6.99 (2.73-17.90) <.001 6.51 (2.07-20.47) .001
Center volume<5 procedures/y* 3.42 (1.52-7.70) .002 1.38 (0.49-3.93) .54
Peripheral vascular disease 9.69 (2.05-45.76) .006 4.42 (0.60-32.69) .14
Cerebrovascular disease 21.11 (2.12-210.31) .005 16.0 (1.02-251.30) .03
Last hemoglobin level 0.80 (0.65-0.99) .037 0.80 (0.63-1.02) .07
CI, Confidence interval; EPP, extrapleural pneumonectomy; OR, odds ratio. *Center volume was individualized to procedure (EPP or PD).
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patients treated with surgery with curative intent suggested
a possible overall survival benefit in patients with stage I un-
dergoing EPP (49 months) compared with PD (23 months).7
Because the superiority of one procedure over another in
providing improved cancer-specific survival is unproven,
an accurate understanding of the operative risk associated
with each procedure is critical.
The current representation of postoperative risk in MPM
surgery is largely based on data from specialty centers.
Therefore, we have sampled the multi-institutional
STS-GTD to determine the frequency of postoperative
morbidity and mortality after EPP and PD in MPM among
a wider variety of surgical centers in the United States. In
this report, in which PD was associated with a mortality
rate of 3.1%, EPP was associated with a mortality rate of
10.5%, generally higher than previously published in large
retrospective series. In the largest single institution series of
328 patients undergoing EPP, Sugarbaker and colleagues15
reported 3.4% operative mortality associated with this
procedure, and in a 3-institution series that included 385TABLE 5. Major morbidity and mortality in patients undergoing pleure
volume
Characteristic
PD
Higher volume 5/y Lower volu
Cases 102 (78.4) 28 (2
ARDS 0 (0.0) 1 (3
Bronchopleural fistula 0 (0.0) 0 (0
Pneumonia 2 (2.0) 1 (3
Reintubation 3 (2.9) 0 (0
Tracheostomy 2 (2.0) 1 (3
Pulmonary embolus 1 (1.0) 1 (3
Empyema 1 (1.0) 0 (0
Sepsis 0 (0.0) 0 (0
Myocardial infarction 1 (1.0) 0 (0
Ventricular arrhythmia requiring treatment 1 (1.0) 0 (0
Bleeding requiring reoperation 0 (0.0) 0 (0
Unexpected return to the operating room 1 (1.0) 1 (3
At least 1 major complication 3 (2.9) 2 (7
Mortality 4 (3.9) 0 (0
At least 1 major complication or mortality 4 (3.9) 2 (7
Length of stay (mean d  SD) 7.9  6.9 9.1 
ARDS, Acute respiratory distress syndrome; EPP, extrapleural pneumonectomy; PD, pleu
34 The Journal of Thoracic and Cardiovascular Surgepatients undergoing EPP, operative mortality was 7%.6 In
our report, EPP also was associated with a higher rate of
major morbidity (24.2%) than PD (3.8%). This is again
generally higher than previously published results,
including those demonstrating 18% serious (grade 3)
or greater adverse events after EPP.6 We therefore
hypothesized that higher center volume might be associated
with decreased mortality and morbidity after surgical
cytoreduction for MPM.
Forty-eight participating centers performed PD or EPP
for MPM; however, only few centers demonstrated a
substantially higher relative volume for either procedure.
Only 3 centers performed more than 5 PDs per year,
and only 2 centers performed more than 5 EPPs per year.
Overall, higher-volume centers seemed to favor PD over
EPP, which may suggest that experienced surgeons
recognize the operative risks of EPP and reserve this
operation for selected patients. We found that the mortality
rate of EPP was lower in higher-volume centers (6.5%)
compared with lower-volume centers (12.5%), although
this did not reach statistical significance.ctomy/decortication or extrapleural pneumonectomy based on center
EPP
me<5/y P value Higher volume 5/y Lower volume<5/y P value
1.5) <.001 31 (32.6) 64 (67.4) <.001
.6) .22 0 (0.0) 8 (12.5) .050
.0) 1.0 0 (0.0) 1 (1.6) 1.0
.6) .52 1 (3.2) 4 (6.2) 1.0
.0) 1.0 4 (12.9) 10 (15.6) 1.0
.6) .52 1 (3.2) 6 (9.4) .42
.6) .39 0 (0.0) 0 (0.0) 1.0
.0) 1.0 0 (0.0) 1 (1.6) 1.0
.0) 1.0 0 (0.0) 4 (6.2) .3
.0) 1.0 0 (0.0) 2 (3.1) 1.0
.0) 1.0 0 (0.0) 2 (3.1) 1.0
.0) 1.0 0 (0.0) 0 (0.0) 1.0
.6) .39 3 (9.7) 6 (9.4) 1.0
.1) .29 6 (19.4) 17 (26.6) .61
.0) .58 2 (6.5) 8 (12.5) .49
.1) .61 6 (19.4) 18 (28.1) .45
13.7 .51 8.3  4.7 10.8  8.3 .052
rectomy/decortication; SD, standard deviation.
ry c July 2014
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(EPP), lower center volume, peripheral vascular disease,
cerebrovascular disease, and low hemoglobin level were
each predictors of postoperative morbidity or mortality,
only procedure (EPP) and the presence of cerebrovascular
disease were independent predictors of this outcome. The
reason for which cerebrovascular disease, and not other
more common risk factors, independently predicted postop-
erative morbidity and mortality is not completely known,
but we speculate that it may in some way be a surrogate
for a less fit surgical candidate.
The selection of EPP or PD for patients with MPM is
based on a number of factors, including tumor burden,
distribution of disease, surgeon preference and experience,
and institutional factors. Although it is likely that center and
surgeon volume and experience do influence morbidity and
mortality outcomes after EPP and PD, our analyses did not
reveal center volume to be an independent predictor of
morbidity or mortality after either of these 2 procedures.
Interpretation of our center volume analyses is constrained
by the limited number of patients in these analyses, and we
believe that the influence of center volume deserves
attention in larger future studies. With further maturation
of the STS-GTD, and with the recent efforts of large
international multi-institutional databases, these analyses
will become more feasible.
Study Strengths and Limitations
The use of a multi-institutional general thoracic surgery
database is one of the strengths of this study. We believe
that our data represent a broader surgeon and center
experience than most previously published reports;
however, there are certainly a number of centers that treat
patients with MPM who are not captured by this database.
Other limitations of this report include its retrospective
study design and the associated selection and information
biases. Although our EPP and PD patient cohorts were
relatively balanced in preoperative characteristics, our
analyses were limited by the absence of histology data
and staging data, and both of these factors are likely to
influence the surgeon’s choice of procedure. It is possible
that EPP in these patients is a marker of more extensive
disease, and that patients who underwent this procedure
had a higher degree of lung involvement. Furthermore,
although a balanced comparison of long-term outcomes of
EPP and PD for patients with MPM also is necessary to
make an informed decision for choice of operation, this
currently cannot be derived from our dataset. Finally, PD
is not a truly standardized operation and completeness of
resection could be variable depending on the operating
surgeon. We approached this by excluding patients
who most likely represented an incomplete resection
(operations coded as pulmonary decortication and parietal
pleurectomy).The Journal of Thoracic and CCONCLUSIONS
In patients withMPM undergoing surgical cytoreduction,
a long-term advantage in survival or recurrence has not
been conclusively demonstrated for either EPP or PD
over one another. Taken together, the results of our
study and the experience of others suggest that PD is
associated with less postoperative morbidity and mortality
than is EPP.References
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